Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Risks of online direct-to-consumer tumor markers for cancer screening.

Lovett KM, Liang BA, Mackey TK.

J Clin Oncol. 2012 May 1;30(13):1411-4. doi: 10.1200/JCO.2011.37.8984. Epub 2012 Feb 21. Review. No abstract available.

PMID:
22355060
2.

Direct-to-consumer disease screening with finger-stick testing: online patient safety risks.

Lovett KM, Liang BA.

Clin Chem. 2012 Jul;58(7):1091-3. doi: 10.1373/clinchem.2012.183103. Epub 2012 Apr 3. No abstract available.

3.

Progress and challenges in colorectal cancer screening and surveillance.

Lieberman D.

Gastroenterology. 2010 Jun;138(6):2115-26. doi: 10.1053/j.gastro.2010.02.006. Epub 2010 Feb 16. Review.

PMID:
20167216
4.

Taishotoyama Symposium Barriers to colorectal cancer screening: economics, capacity and adherence.

Inadomi JM.

J Gastroenterol Hepatol. 2008 Dec;23 Suppl 2:S198-204. doi: 10.1111/j.1440-1746.2008.05556.x.

PMID:
19120898
5.

The marketing of osteoporosis.

Napoli M.

Am J Nurs. 2009 Apr;109(4):58-61. doi: 10.1097/01.NAJ.0000348606.24360.7d. Review. No abstract available.

PMID:
19325320
6.

Direct-to-consumer advertising of prescription drugs: balancing benefits and risks, and a way forward.

Kravitz RL, Bell RA.

Clin Pharmacol Ther. 2007 Oct;82(4):360-2. No abstract available.

PMID:
17851573
7.

Patient education regarding cancer screening guidelines.

Mahon SM.

Clin J Oncol Nurs. 2003 Sep-Oct;7(5):581-4. Review.

PMID:
14603556
8.

[Large part of Swedish men PSA tested for early prostatic cancer. Few aware of the disadvantages of the test].

Bratt O, Grenabo L.

Lakartidningen. 2010 Feb 17-23;107(7):432-5. Swedish. No abstract available.

PMID:
20384075
9.

An assessment of direct-to-consumer advertising of prescription drugs.

Calfee JE.

Clin Pharmacol Ther. 2007 Oct;82(4):357-60.

PMID:
17851572
10.

Personalizing ovarian cancer screening.

Goozner M.

J Natl Cancer Inst. 2010 Aug 4;102(15):1112-3. doi: 10.1093/jnci/djq296. Epub 2010 Jul 28. No abstract available.

PMID:
20668268
11.

Does direct-to-consumer marketing of medical technologies undermine the physician-patient relationship?

Rosenberg L.

Am J Bioeth. 2009 Apr;9(4):22-3. doi: 10.1080/15265160802716852. No abstract available.

PMID:
19326306
12.

The economics of improved cancer survival rates: better outcomes, higher costs.

Uyl-de Groot CA, de Groot S, Steenhoek A.

Expert Rev Pharmacoecon Outcomes Res. 2010 Jun;10(3):283-92. doi: 10.1586/erp.10.27. Review.

PMID:
20545593
13.

Ovarian cancer: screening for early detection.

Harris LL.

Am J Nurs. 2002 Oct;102(10):46-52; quiz 53. Review. No abstract available.

PMID:
12394306
14.

Principles of Cancer Screening.

Pinsky PF.

Surg Clin North Am. 2015 Oct;95(5):953-66. doi: 10.1016/j.suc.2015.05.009. Epub 2015 Jun 20. Review.

15.

Principles of cancer prevention and early detection.

Mahon SM.

Clin J Oncol Nurs. 2000 Jul-Aug;4(4):169-76. Review.

PMID:
11261098
16.

Progress report on ovarian cancer screening. Scientists are making headway in detecting ovarian cancer at an earlier stage.

[No authors listed]

Harv Womens Health Watch. 2010 Apr;17(8):1-3. No abstract available.

PMID:
20506601
17.

Direct-to-consumer advertisements of prescription drugs.

Council on Ethical and Judicial Affairs of the American Medical Association..

Food Drug Law J. 2000;55(1):119-24. No abstract available.

PMID:
12322719
18.

Testing for prostate cancer. A consumer view.

Gardner M.

Aust Fam Physician. 2003 Jun;32(6):398-9. No abstract available.

PMID:
12833762
19.

Physician advertising: some reasons for caution.

Yarborough M.

South Med J. 1989 Dec;82(12):1538-44.

PMID:
2595422
20.

Medicolegal Sidebar: Informed Consent in the Information Age.

Bal BS, Brenner LH.

Clin Orthop Relat Res. 2015 Sep;473(9):2757-61. doi: 10.1007/s11999-015-4440-5. Epub 2015 Jul 7. No abstract available.

Supplemental Content

Support Center